Form 4 for IRMD IRADIMED CORP
Accepted 2025-12-10 00:00:00 ET · period of report 2025-12-07 · accession 0001253497-25-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-10 | 2025-12-07 | IRMD | GLENN JOHN | CFO | F - Tax | $94.57 | -11.7K | 9,621 | -55% | -$1.10M |
| DM | 2025-12-10 | 2025-12-07 | IRMD | GLENN JOHN | CFO | M - OptEx | — | +31.5K | 13.0K | New | — |
| DM | 2025-12-10 | 2025-12-07 | IRMD | GLENN JOHN | CFO | M - OptEx | $0.00 | -31.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-07 | F | D | 8,267 | $94.57 | 22,362 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-07 | M | A | 21,008 | — | 30,629 | D | — | — | (F2) If the relative measure at December 7, 2025 and for the three-year period then ended is: (i) less than or equal to 80% of the peer group, no vesting would occur, (ii) between 80% and 100% of the peer group, the number of shares vesting would be pro-rata against the nominal granted shares, (iii) equal to 100% of the peer group, the number of shares vesting would be the nominal granted shares, (iv) between 100%and 120% of the peer group, the number of shares vesting would be pro-rata against an additional tranche of the nominal granted shares plus the nominal granted shares, and (v) if 120% or greater of the peer group, the number of shares vesting would be double the nominal granted shares. |
| 3 | Common | Common Stock | 2025-12-07 | F | D | 3,383 | $94.57 | 9,621 | D | — | — | |
| 4 | Common | Common Stock | 2025-12-07 | M | A | 10,504 | — | 13,004 | D | — | — | (F1) Restricted stock units convert into common stock on a one-for-one basis. |
| 5 | Derivative | Restricted Stock Units | 2025-12-07 | M | D | 10,504 | $0.00 | 0 | D | — · — to — | 10,504 Common Stock | (F1) Restricted stock units convert into common stock on a one-for-one basis. (F3) The reporting person received restricted stock units ("RSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. The RSUs vest in full on the third anniversary of the grant date, December 7, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. |
| 6 | Derivative | Performance-based Restricted Stock Units | 2025-12-07 | M | D | 21,008 | $0.00 | 0 | D | — · — to — | 21,008 Common Stock | (F2) If the relative measure at December 7, 2025 and for the three-year period then ended is: (i) less than or equal to 80% of the peer group, no vesting would occur, (ii) between 80% and 100% of the peer group, the number of shares vesting would be pro-rata against the nominal granted shares, (iii) equal to 100% of the peer group, the number of shares vesting would be the nominal granted shares, (iv) between 100%and 120% of the peer group, the number of shares vesting would be pro-rata against an additional tranche of the nominal granted shares plus the nominal granted shares, and (v) if 120% or greater of the peer group, the number of shares vesting would be double the nominal granted shares. (F4) On December 7, 2022, the reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. Vesting of these PRSUs depends on the reporting person's achievement of specified relative ranking of total shareholder return over a three-year period from December 8, 2022 through December 7, 2025. |